Objective: The aim of the present study was to determine the effects of angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin II type 1 receptor (AT-1 receptor) blocker on the progression of rat hepatic fibrosis induced by CCl4.
Methods: 60 male wistar rats weighting about 250 g were divided into 4 groups. Model group (Mo): The rats were injected with 40% CCl(4) 0.25 ml/100 g subcutaneously three times a week. Perindopril group (Pe): The rats were injected with 40% CCl(4). Perindopril, equivalent to 2 mg x kg(-1) x d(-1), was given i.g. Losartan group (Lo): The rats were injected with 40% CCl(4). Losartan, equivalent to 50 mg x kg(-1) x d(-1), was given i.g. Control group (Nc): the rats were injected with olive oil only. After 4, 6 weeks, morphological examination was based on microscopy. RT-PCR was utilized to detect gene expression of AT-1 receptor in the liver. Meanwhile, the protein expressions of AT-1 receptor, TGF-beta1 and PDGF-BB in liver tissue were examined by Western blot. The activity of matrix metalloproteinase-2 (MMP-2) was assessed by zymography. Serum laminin (LN) and hyaluronic acid (HA) were measured using radioimmunoassays.
Results: RT-PCR and Western blot revealed that there was a up-regulation in AT-1 receptor expression in model group compared with control group. Both of perindopril and losartan treatment significantly reduced mean fibrosis score, messenger RNA and protein levels of AT1 receptor, protein levels of TGF-beta1 and PDGF-BB, Serum levels of HA and LN, and MMP-2 activity.
Conclusion: These results suggest that angiotensin IImay play an important role in fibrosis of liver. Perindopril and losartan may have inhibiting effects on CCl(4)-induced hepatic fibrogenesis of rat.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effect of Lemborexant on Daytime Functioning in Adults With Insomnia: Patient-Reported Outcomes From a Phase 3 Clinical Trial.
Prim Care Companion CNS Disord
January 2025
Eisai Inc, Nutley, New Jersey.
Insomnia and some insomnia treatments can impact an individual's daytime functioning. Here, we performed post hoc analyses of patient-reported outcomes from a phase 3 clinical trial to assess the impact of lemborexant (LEM), a dual orexin receptor antagonist, on daytime functioning. Adults with insomnia were randomized 1:1:1 to receive placebo, LEM 5 mg (LEM5) or LEM 10 mg (LEM10) for 6 months.
View Article and Find Full Text PDFAssociation of Antihypertensive and Statin Medication Usage With Postoperative Stiffness After Arthroscopic Rotator Cuff Repair: A Retrospective Cohort Study.
Orthop J Sports Med
January 2025
Rothman Orthopaedic Institute, Philadelphia, Pennsylvania, USA.
Background: Angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), and statins may be able to modulate postoperative stiffness, a major cause of morbidity after arthroscopic rotator cuff repair (aRCR).
Purpose: To determine whether there is an association between ACEi, ARB, or statin usage and stiffness after aRCR.
Study Design: Cohort study; Level of evidence, 3.
Phosphoproteomics for studying signaling pathways evoked by hormones of the renin-angiotensin system: A source of untapped potential.
Acta Physiol (Oxf)
February 2025
Department of Molecular Medicine, Cardiovascular and Renal Research Unit, University of Southern Denmark, Odense M, Denmark.
The Renin-Angiotensin System (RAS) is a complex neuroendocrine system consisting of a single precursor protein, angiotensinogen (AGT), which is processed into various peptide hormones, including the angiotensins [Ang I, Ang II, Ang III, Ang IV, Ang-(1-9), Ang-(1-7), Ang-(1-5), etc] and Alamandine-related peptides [Ang A, Alamandine, Ala-(1-5)], through intricate enzymatic pathways. Functionally, the RAS is divided into two axes with opposing effects: the classical axis, primarily consisting of Ang II acting through the AT receptor (ATR), and in contrast the protective axis, which includes the receptors Mas, ATR and MrgD and their respective ligands. A key area of RAS research is to gain a better understanding how signaling cascades elicited by these receptors lead to either "classical" or "protective" effects, as imbalances between the two axes can contribute to disease.
View Article and Find Full Text PDFLerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.
Nat Commun
January 2025
Genor Biopharma Co., Ltd, Beijing, China.
Lerociclib (GB491), a highly selective oral CDK4/6 inhibitor, has displayed anti-tumor activity and differentiated safety and tolerability profile in previous ph1/2 clinical trials. The LEONARDA-1, a randomized, double-blind, phase III study, was conducted to evaluate the efficacy and safety of lerociclib in HR+/HER2- locally advanced or metastatic breast cancer patients, who had relapsed or progressed on prior endocrine therapy. A total of 275 patients were randomized at 1:1 ratio to receive lerociclib (137 patients, 150 mg twice daily) or placebo (138 patients) plus fulvestrant.
View Article and Find Full Text PDFThe antihyperglycemic activity of extracellular polysaccharopeptides (ePSP) obtained from Trametes versicolor (TV) strain LH-1 has been demonstrated in hepatic cells and diabetic animals. This study further investigated the mechanisms of T. versicolor-ePSP on regulating glucose metabolism, including insulin signaling molecules and glucose metabolism-associated enzymes, in the liver of rats with type 2 diabetes mellitus (T2DM).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!